Form 4: Royalty Pharma EVP Sells Shares Under 10b5-1 Plan

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 20,000 Class A Ordinary Shares for $40.78 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• Marshall Urist, EVP, Research & Investments at Royalty Pharma plc, sold 20,000 Class A Ordinary Shares.
• The sale occurred on January 9, 2026, at a weighted average price of $40.7817 per share, with individual transactions ranging from $40.57 to $40.97.
• The transaction was executed under a Rule 10b5-1 trading plan adopted by Mr. Urist on September 16, 2025.
• Following the sale, Mr. Urist directly owns 7,398 Class A Ordinary Shares and indirectly owns 60,000 shares via Sandy Lamm LLC and 19,020 shares via an IRA.
• Mr. Urist also holds limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd (RPH) exchangeable into 1,356,528 Class A Ordinary Shares, with RPH Class E shares subject to vesting conditions.

Sentiment

Score: 6

Explanation: The sale of shares by an executive is generally a neutral to slightly negative signal. However, the execution under a pre-arranged 10b5-1 plan significantly mitigates any negative implications, as it indicates the transaction was not based on new, non-public information. The executive also retains substantial direct and indirect holdings.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was not based on new, non-public information and is a planned financial diversification.
• The reporting person retains significant beneficial ownership, including substantial exchangeable interests, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct equity stake of a key executive.

Risks

• While the sale was pre-planned, significant insider selling could be perceived negatively by the market, potentially impacting investor sentiment.

Future Outlook

NA

Industry Context

This Form 4 filing reflects a routine insider transaction for an executive at a biopharmaceutical royalty company. Such transactions are common for executives managing personal finances and are often pre-scheduled, especially when executed under a 10b5-1 plan, which aims to avoid accusations of trading on inside information. Royalty Pharma operates in a specialized segment of the biopharma industry, acquiring royalties on approved and late-stage pharmaceutical products.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan should alleviate concerns about negative company prospects. The executive's continued significant holdings maintain alignment.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

The insider sale by EVP Marshall Urist, while a reduction in direct equity, was conducted under a pre-established 10b5-1 plan, which typically signals a planned financial diversification rather than a reaction to new, adverse company information. The executive retains substantial direct and indirect beneficial ownership, including significant exchangeable interests, maintaining alignment with shareholder value. This transaction alone does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Royalty Pharma, RPRX, Marshall Urist, Insider Sale, Form 4, 10b5-1 Plan, Executive Compensation, Share Sale, Equity Transaction, Biopharma Royalties